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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.06.005The risk associated with arterial thromboembolism (ATE) increases with the presence of anti-vascular
endothelial growth factor (VEGF). We are reporting a case of transient ischemic attack (TIA) due to steno-
sis of the carotid and brachiocephalic arteries following long-term treatment with sorafenib for renal cell
carcinoma (RCC). The patient is a non-smoker with no known comorbidities and had no history of car-
diovascular disease. The patient underwent a right endarterectomy with angioplasty, aortic arch, and
brachiocephalic artery angiogram with a stent placed in the brachiocephalic artery.HThis is a case of 45-year-old male non-smokerwith no known comorbidities and no historyof cardiovascular disease. He presented after
three episodes of painless hematuria in March 2001.
He was diagnosed with renal cell carcinoma (RCC,
stage T1, N0, M0), for which he underwent a left rad-
ical nephrectomy. Later pathology revealed a clear cell
carcinoma and granuloma; and a computed tomogra-
phy (CT) scan indicated no metastasis.
At a routine follow-up in March 2007, a CT scan
revealed a soft tissue mass in the kidney bed, suggest-
ing local recurrence with liver lesions and retroperito-
neal lymph nodes. Accordingly, the patient was started
on sorafenib (400 mg orally twice a day). The patient
then had multiple CT follow-up scans, all of which
showed ﬂuctuating measurement of liver lesions and
lymph nodes and unchanged soft tissue in the renal
bed. The results were considered an indication of sta-
ble disease, so treatment with sorafenib was continued.
In November 2009, the patient was referred to
medical oncology for further management. The pa-
tient also reported symptoms of fever, sweating, and
weight loss, as well as a history of contact with open
tuberculosis. Accordingly, the patient had ﬁne-needle
aspiration (FNA) of one of the retroperitoneal lymph
nodes. The results were negative for malignant cells
but with the presence of granulomatous inﬂammation
with negative acid-fast bacilli. The treatment plan was
to start anti-tuberculosis treatment and to continue
sorafenib because the whole picture suggested bothematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comtuberculosis and RCC relapse. The anti-tuberculosis
therapy included isoniazide, ethambutol, moxiﬂoxa-
cin, and pyridoxine, none of which have documented
drug interaction with sorafenib. The patient’s consti-
tutional symptoms improved, and the anti-tuberculo-
sis treatment was continued for the next 18 weeks.
In May 2011, the patient presented with a history
of left-side facial and body weakness for three min-
utes. A CT scan revealed an incidental bilateral caro-
tid artery stenosis. Further CT scans of the aortic
arch revealed tight focal stenosis in the proximal
brachiocephalic artery [Figs. 1 and 2]. The internal
and external carotid arteries were patent. Also identi-
ﬁed was a moderate focal stenosis at the origin of the
left common artery, with no other stenosis seen in the
rest of the left carotid arteries. A CT scan of the brain
was negative.
Ultrasound doppler of the carotids revealed severe
stenosis at the thoracic part of the right common car-
otid and the right brachiocephalic artery. Also found
were multiple continuous soft atheromatous plaques
throughout the right common carotid, resulting in a
60% distal common carotid stenosis. The internal
and external carotid arteries were found to be patent
but with lower transmitted systolic velocity and wave-
form of the distal right internal carotid artery (ICA)
high in the neck, almost ﬂat (tardus parvus from the
carotid bulb upward), with peak systolic velocities
ranging between 25 and 24 cm. The left internal and
external carotid arteries had no stenosis, with normal53
Figure 1. Left upper extremity angiogram shows stenosis in the proximal brachiocephalic artery.
Figure 2. CT aortic arch shows tight focal stenosis in the proximal brachiocephalic artery. Distal to this, the right common carotid, internal carotid
and external carotid arteries have diffuse small calibers but are patent. There is also moderate focal stenosis at the origin of the left common
carotid artery.
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ent with normal ﬂow.
In July 2011, the patient underwent a right endar-
terectomy with bovine patch angioplasty, an aortic
arch and brachiocephalic artery angiogram, and a
stent placement in the brachiocephalic artery, and
he was started on clopidogrel with aspirin. His lipid
proﬁle (cholesterol 228 mg/dl, HDL 45 mg/dl,
LDL 147 mg/dl), and atorvastatin was later
prescribed.
At that time, a decision was made to discontinue
sorafenib due to the new onset of endarterectomy
arterial stenosis that presented with transient ischemic
attack (TIA) and the perceived reduced likelihood of
RCC recurrence. Two years later, and without sorafe-
nib therapy, there has been no recurrence of RCC. In
total, the patient was prescribed sorafenib for 4 years,
which is a relatively long duration.
During sorafenib treatment, the patient developed
hypertension (blood pressure always above 150/
90 mmHg), although this was not treated. Urine
dipsticks taken at the time never reported more thanHe+1 protein. Other laboratory tests performed were al-
ways within normal limits, including complete blood
counts with differential, renal, and live function tests.
The only side effects identiﬁed were grade-one hand-
foot syndrome and diarrhea during the sorafenib ther-
apy period.DISCUSSION
Sorafenib is a tyrosine kinase inhibitor (TKIs) that
targets the vascular endothelial growth factor (VEGF).
Reported side effects include hypertension, protein-
uria, increased risk of bleeding, thromboembolism,
hypothyroidism, and gastrointestinal perforation.
We are reporting a case of TIA due to stenosis of
the carotid and brachiocephalic arteries following
4 years of sorafenib treatment for RCC.
Our search did not identify any reported carotid ar-
tery stenosis with the use of anti-VEGF drugs such as
sorafenib, sunitinib, pazopanib, axitinib, vandetanib,
and regorafenib, as well as anti-VEGF antibodies such
as bevacizumab. Our search did, however, identify twomatol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.com
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cases where sorafenib was prescribed and carotid ar-
tery stenosis was reported to the FDA through the
Adverse Event Reporting System (AERS), as listed
on the DrugCite website.1
The risk of arterial thromboembolism (ATE) asso-
ciated with anti-VEGF was assessed in two meta-anal-
yses.2,3 The ﬁrst meta-analysis involved bevacizumab,
a monoclonal antibody, and the incidence of all grades
of ATE were 3.3% (95% CI, 2.0–5.6%), with relative
risk (RR) of 2.08 (95% CI, 1.28–3.40; p = 0.013)
compared to controls.2 Interestingly, the analysis also
found that bevacizumab signiﬁcantly increased the risk
of high-grade ATE in patients with RCC RR 5.14
(95% CI 1.35–19.64, p = 0.029) compared to other
solid tumors. However, the risk of cardiac ischemia
but not stroke was higher with bevacizumab than in
the control group. The second meta-analysis involved
sorafenib and sunitinib, TKIs; the incidence of ATE
was 1.4% (95% CI 1.2–1.6%) with RR 3.03 (95%
CI 1.25–7.37; p = 0.015) compared to controls.3 This
risk, however, did not differ between the two TKIs
(sorafenib versus sunitinib) or tumor types (renal ver-
sus non-renal cell carcinoma).
Even though our patient developed ATE with the
long-term use of an anti-VEGF, there are reportedHematol Oncol Stem Cell Ther 7(1) First Quarter 2014 hemoncstem.edmgr.comcases with much shorter duration of use. There was
a report of two cases of cerebrovascular incidents with
sorafenib in hepatocellular carcinoma.4 In both cases,
the patients had no risk factors for cerebrovascular
events except gender and age in the second case. Both
had normal carotid ultrasounds and normal ECHO.
In these cases, both experienced stroke within
5 weeks, which is considered a relatively short time
with no development of hypertension.
The risk of ATE seems to be related to atheroscle-
rosis. A study in mice revealed that systemic VEGF
inhibition disrupts endothelial homeostasis, acceler-
ates atherogenesis, and can cause a 33% increase in
atherosclerotic lesions.5
In our case, the carotid stenosis occurred after
4 years, which may be related to the cumulative dose
of sorafenib. A recent phase I/II study using sorafenib
for solid tumors found the development of grade two
and three hand-foot syndrome was associated with
cumulative sorafenib exposure (p = 0.0008).6CONFLICT OF INTEREST
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